Table 4.

Most common adverse events by treatment group, age, and type of neuropathic pain.

		Placebo, n (%)		Pregabalin 150 mg/day, n (%)		Pregabalin 300 mg/day, n (%)		Pregabalin 600 mg/day, n (%)
Adverse effect	Age range (years)	DPN	PHN	DPN	PHN	DPN	PHN	DPN	PHN
		(n = 558)	(n = 363)	(n = 176)	(n = 251)	(n = 266)	(n = 230)	(n = 513)	(n = 159)
Dizziness	18–64	16 (4.4)	9 (13.2)	7 (5.5)	4 (7.0)	40 (22.0)	11 (24.0)	85 (24.7)	23 (48.9)
	65–74	8 (5.1)	10 (7.0)	3 (7.7)	13 (14.1)	16 (25.8)	25 (39.1)	46 (33.1)	25 (36.2)
	≥75	2 (5.9)	17 (11.2)	2 (20.0)	22 (21.6)	6 (27.3)	37 (30.6)	11 (36.7)	13 (30.2)
Somnolence/ sedation	18–64	14 (3.8)	5 (7.4)	5 (3.9)	7 (12.3)	24 (13.2)	3 (6.7)	45 (13.1)	13 (27.7)
	65–74	2 (1.3)	5 (3.5)	2 (5.1)	9 (9.8)	11 (17.7)	14 (21.9)	16 (11.5)	20 (29.0)
	≥75	0	10 (6.6)	2 (20.0)	12 (11.8)	3 (13.6)	25 (20.7)	7 (23.3)	11 (25.6)
Peripheral edema	18–64	27 (7.4)	2 (2.9)	6 (4.7)	3 (5.3)	15 (8.2)	3 (6.7)	53 (15.4)	6 (12.8)
	65–74	10 (6.3)	6 (4.2)	3 (7.7)	9 (9.8)	9 (14.5)	8 (12.5)	24 (17.3)	12 (17.4)
	≥75	3 (8.8)	6 (3.9)	1 (10.0)	7 (6.9)	2 (9.1)	24 (19.8)	5 (16.7)	4 (9.3)
Infection	18–64	25 (6.8)	2 (2.9)	10 (7.9)	9 (15.8)	17 (9.3)	4 (8.9)	10 (2.9)	1 (2.1)
	65–74	8 (5.1)	7 (4.9)	4 (10.3)	7 (7.6)	5 (8.1)	3 (4.7)	6 (4.3)	1 (1.4)
	≥75	2 (5.9)	3 (2.0)	0	6 (5.9)	1 (4.5)	11 (9.1)	1 (3.3)	2 (4.7)
Dry mouth	18–64	6 (1.6)	2 (2.9)	1 (0.8)	5 (8.8)	6 (3.3)	0	18 (5.2)	8 (17.0)
	65–74	1 (0.6)	6 (4.2)	0	9 (9.8)	4 (6.5)	6 (9.4)	10 (7.2)	9 (13.0)
	≥75	0	5 (3.3)	2 (20.0)	5 (4.9)	3 (13.6)	8 (6.6)	2 (6.7)	6 (14.0)
Weight gain	18–64	3 (0.8)	1 (1.5)	6 (4.7)	3 (5.3)	9 (4.9)	4 (8.9)	34 (9.9)	5 (10.6)
	65–74	1 (0.6)	2 (1.4)	1 (2.6)	1 (1.1)	1 (1.6)	2 (3.1)	10 (7.2)	9 (13.0)
	≥75	1 (2.9)	0	1 (10.0)	1 (1.0)	0	8 (6.6)	1 (3.3)	5 (11.6)

This table has been modified from Semel et al. [2010].